First Phase 1b, single-center, age de-escalation trial of the<i>P. falciparum</i>blood-stage malaria vaccine candidate RH5.1/Matrix-M™: a delayed boost regimen induces high levels of functional antibodies in 5-17 month old Tanzanian infants
medRxiv (Cold Spring Harbor Laboratory)